* Applied Spectral Imaging, of Migdal Ha'emek, Israel, received No. 5,798,262, covering the field of color karyotyping used for chromosome classification.
* Perkin-Elmer Corp., of Norwalk Conn., reported its Foster City, Calif.-based division PE Biosystems received No. 5,800,996, "Energy Transfer Dyes with Enhanced Fluorescence." The patent describes a new class of fluorescent dye compounds that are well-suited as labels in automated DNA sequencing processes.
* Procyon BioPharma Inc., of London, Ontario, received No. 5,780,033, covering the production and use of its non-pathogenic antinuclear autoantibodies for the treatment of cancer.
* Regeneron Pharmaceuticals Inc., of Tarrytown, N.Y., received No. 5,814,464 covering the gene that encodes the human angiopoietin-2 (Ang2) protein and a method of using the gene to make the Ang2 protein. Ang2 is a natural antagonist of angiopoietin-1, Regeneron's growth factor that promotes blood vessel growth and may have a role in the development and growth of blood cells.
* Repligen Corp., of Needham, Mass., received No. 5,795,860, covering the methods of blocking the activity of a protein with a drug that inhibits the binding of the protein to a class of heparin-like carbohydrates known as glycosaminoglycans.
* SuperGen Inc., of San Ramon, Calif., received No. 5,802,568, covering Extra, an improved drug reformulation technology. Extra technology uses an inert chemical which, when added to an existing anticancer drug, makes it water-soluble and protects the patient's skin from tissue damage at the injection site.
* Synsorb Biotech Inc., of Calgary, Alberta, received No. 5,780,603, covering the directed combinatorial synthesis of carbohydrate libraries.
* Triangle Pharmaceuticals Inc., of Durham, N.C., reported that Emory University, of Atlanta, received No. 5,814,639, for the compound Beta-2-Deoxy-5-fluro-3-thiacytidine, also known as FTC. Triangle has the worldwide exclusive license to purified forms of FTC in the HIV and HBV fields.
* Unigene Laboratories Inc., of Fairfield, N.J., received No. 5,789,234, for its manufacturing process for calcitonin and other amidated peptides.
* Vertex Pharmaceuticals Inc., of Cambridge, Mass., received No. 5,807,876, which claims a class of compounds that includes Vertex's lead IMPDH inhibitor, VX-497, pharmaceutical compositions containing these compounds, and the use of those compositions for the treatment of autoimmune and viral diseases. VX-497, which targets the inosine monophosphate dehydrogenase enzyme (IMPDH), is in clinical development for the treatment of hepatitis C and autoimmune diseases.
* Xenometrix Inc., of Boulder, Colo., received No. 5,811,231, "Methods and Kits for Eukaryotic Gene Profiling." The company shares the patent with Harvard University, of Cambridge, Mass., and has the exclusive worldwide license to Harvard's ownership. The patent covers the creation of many multigene expression profiles resulting from exposure of eukaryotic cells, including human, animal and yeast cells, to pharmaceutical compounds and other chemical entities.